Proteome Sciences PLC Director/PDMR Shareholding (3668W)
July 31 2018 - 11:09AM
UK Regulatory
TIDMPRM
RNS Number : 3668W
Proteome Sciences PLC
31 July 2018
31 July 2018
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Director/PDMR Shareholding
The Company has received notification from Vulpes Life Sciences
Fund ("Vulpes") that on 27 July 2018, it purchased 525,000 ordinary
shares and 118,000 ordinary shares of 1p each in the capital of the
Company ("Ordinary Shares") at 3.49p and 3.5p respectively per
Ordinary Share (the "Purchase"). Following the purchase, Vulpes has
a total direct and indirect interest in 56,031,431 equivalent to
18.98% of Proteome Sciences' total issued share capital.
The Company would also like to announce that by virtue of Martin
Diggle being a Director of both Vulpes Investment Management and
the Company, he now has an interest in 56,031,431 Ordinary Shares
of the Company representing 18.98% of the issued share capital of
the Company.
The below notification is made in accordance with the
requirements of the EU Market Abuse Regulation.
1. Details of the person discharging managerial responsibilities/person
closely associated
a) Name: Martin Diggle
----------------------------------------- --------------------------------------
Reason for the notification
---------------------------------------------------------------------------------
a) Position/status: Non-Executive Director
----------------------------------------- --------------------------------------
b) Initial notification/Amendment: Initial Notification
----------------------------------------- --------------------------------------
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------------
a) Name: Proteome Sciences Plc
----------------------------------------- --------------------------------------
b) LEI: 213800Q62ICXANKU2986
----------------------------------------- --------------------------------------
Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------------------
a) Description of the financial instrument, Ordinary Shares of 1p nominal
type of instrument: value
Identification code: GB0003104196
----------------------------------------- --------------------------------------
b) Nature of the transaction: Purchase of Ordinary Shares
----------------------------------------- --------------------------------------
c) Price(s) and volume(s): Price(s) Volume(s)
3.49 525,000
----------
3.5 118,000
----------
----------------------------------------- --------------------------------------
d) Aggregated information: Single transaction as in
* Aggregated volume: 4 c) above Average Price Volume(s)
3.492 643,000
----------
* Price:
----------------------------------------- --------------------------------------
e) Date of the transaction: 27 July 2018
----------------------------------------- --------------------------------------
f) Place of the transaction: London Stock Exchange,
AIM (XLON)
----------------------------------------- --------------------------------------
For further information:
Proteome Sciences plc
Dr Jeremy Haigh, Chief Executive Tel: +44 (0)20 7043 2116
Officer
Dr Ian Pike, Chief Scientific Officer
Richard Dennis, Chief Commercial
Officer
finnCap Limited (Nominated Adviser & Broker)
Geoff Nash/Hannah Boros (Corporate Tel: +44 (0)20 7220 0500
Finance)
Abigail Wayne (Broking)
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences is a leader in applied proteomics offering
high sensitivity, proprietary technologies and workflows for
mapping cell signalling pathways (SysQuant(R) ) and for the
discovery, validation and assay development of protein biomarkers
(TMTcalibrator(TM) ). The company has its headquarters in London,
UK, with laboratory facilities in Frankfurt, Germany from where the
PS Biomarker Services(TM) division provides outsourced proteomics
services and proprietary biomarker assays to biopharmaceutical and
diagnostics companies and to academia.
Proteome Sciences has patented several novel protein biomarkers
for diagnostic and treatment applications in important areas of
human therapeutics such as cancer, stroke and Alzheimer's disease,
and these are available for license.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHSDWFIFFASESW
(END) Dow Jones Newswires
July 31, 2018 11:09 ET (15:09 GMT)
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From Apr 2023 to Apr 2024
